A Comprehensive Longitudinal Cohort Study in Type 2 Diabetes With High Risk of Cardiovascular Diseases in China (CCMR-3B Ext)

Study Description

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

In 2010, the sponsor conducted an observational study, entitled as "Nationwide Assessment of Cardiovascular Risk Factors: Blood Pressure, Blood Lipid, and Blood Glucose, in Chinese Patients with Type 2 Diabetes - 3B Study " which was to evaluate the level of cardiovascular diseases (CVD) risk factor control and its regional difference in China. As a continuation, this extension of the 3B Study is designed to assess the incidence of cardiovascular events, cardio-renal events, and other microvascular complications, in 1, 2 and 3 years in patients with type 2 diabetes and with high risk of (CVD) with or without existing or history of coronary artery diseases.

Condition or disease
Type 2 Diabetes

Detailed Description:

Limited by its cross sectional design, 3B study was not be able to provide any information on how various patterns of treatment and prescribing behaviors would impact the outcomes of prevention of cardiovascular and cardio-renal diseases in type 2 diabetes longitudinally. This information, however, would be crucial in better guiding the real world medical practice and maximizing the effectiveness of medical treatment for better controlling cardiovascular risk factors.

The 3B Extension study is thus designed to extend the 3B study by continuing to follow up on enrolled patients for 3 years. The 3B Extension study is expected to demonstrate the clinical outcomes of nationally representative type 2 diabetes patients who are treated by endocrinologists, cardiologists and nephrologists separately in all tiers of hospitals, as measured by diabetes progression, incidence of cardiovascular complications, and incidence of microvascular complications. It will be the first study of this scale in China based on its exclusivity, extensiveness, and the level of government and national thought leaders' support. It will be conducted in collaboration with the advisory board of China Cardiometabolic Registries (CCMR).

Study Design

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Observational
Estimated Enrollment :	5000 participants
Observational Model:	Cohort
Time Perspective:	Prospective
Official Title:	A Comprehensive Longitudinal Cohort Study in Type 2 Diabetes With High Risk of Cardiovascular Diseases in China - 3B Extension A Study of China Cardiometabolic Registries (CCMR)
Study Start Date :	March 2011
Estimated Primary Completion Date :	May 2014
Estimated Study Completion Date :	December 2014

Groups and Cohorts

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
with CAD; Patients with hypertension and dyslipidemia with prior CAD
without CAD; Patients with hypertension and dyslipidemia without prior CAD

Outcome Measures

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Incidence of CVD events [ Time Frame: 3 years ]

   The CVD event is defined as composite of :

   • Acute myocardial infarction
   • Stroke
   • Cardiovascular death

Secondary Outcome Measures :

1. Annual incidence of microvascular complications [ Time Frame: 3 years ]

Eligibility Criteria

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	40 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

Patients with type 2 diabetes who previously participated in the 3B study from either community (tier 1), regional (tier 2), or teriary (tier 3) hospitals

Criteria

Inclusion Criteria:

• Age 40 years or older
• Outpatients who meet the inclusion and exclusion criteria of 3B study
• With hypertension,dyslipidemia and one of the following:
• History of acute coronary artery disease or ischemic stroke
• Age > 65 years old
• Overweight or obesity (BMI > 24 kg/m2)
• Microalbuminuria or albuminuria
• Current smoker

Exclusion Criteria:

• Patients with type 1 DM
• Pregnant or breast feeding women
• Patients who are unable to or not willing to return for follow up visits every 6 months for 3 years;
• Patients have severe heart failure (NYHA Class III-IV)
• Patients with severe renal deficiency (creatinine clearance < 30 ml/min)
• Patients who are not willing to sing the informed consent form;
• Patients who are participating in any other interventional clinical studies,

Contacts and Locations

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Sponsors and Collaborators

China Cardiometabolic Registries

Merck Sharp & Dohme Corp.

VitalStrategic Research Institute

Gerontological Society of China

Chinese Medical Doctor Association

Investigators

Principal Investigator:	Linong Ji, MD	People's Hospital, Beijing University
Principal Investigator:	Dayi Hu, MD	People's Hospital, Beijing University

More Information

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Additional Information:

Website for China Cardiometabolic Registries 

Responsible Party:	China Cardiometabolic Registries
ClinicalTrials.gov Identifier:	NCT01307410 History of Changes
Other Study ID Numbers:	CCMR-303-3B Extension
First Posted:	March 2, 2011
Last Update Posted:	February 15, 2013
Last Verified:	February 2011

Keywords provided by China Cardiometabolic Registries:

Patients with type 2 diabetes and participated in 3B Study

Additional relevant MeSH terms:

Diabetes Mellitus; Diabetes Mellitus, Type 2; Cardiovascular Diseases	Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases